[1] WU T,DAI Y.Tumor microenvironment and therapeutic response [J].Cancer Lett,2017,387:61-68.
[2] PITT JM,MARABELLE A,EGGERMONT A,et al.Targeting the tumor microenvironment:removing obstruction to anticancer immune responses and immunotherapy [J].Ann Oncol,2016,27(8):1482-1492.
[3] MAAS RR,SOUKUP K,FOURNIER N,et al.The local microenvironment drives activation of neutrophils in human brain tumors [J].Cell,2023,186(21):4546-4566.e4527.
[4] IASONOS A,SCHRAG D,RAJ GV,et al.How to build and interpret a nomogram for cancer prognosis [J].J Clin Oncol,2008,26(8):1364-1370.
[5] FENG F,TIAN Y,XU G,et al.Diagnostic and prognostic value of CEA,CA19-9,AFP and CA125 for early gastric cancer [J].BMC Cancer,2017,17(1):737.
[6] AJANI JA,D'AMICO TA,BENTREM DJ,et al.Gastric cancer,version 2.2022,NCCN clinical practice guidelines in oncology [J].J Natl Compr Canc Netw,2022,20(2):167-192.
[7] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].CA Cancer J Clin,2018,68(6):394-424.
[8] LI L,YU R,CAI T,et al.Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment [J].Int Immunopharmacol,2020,88:106939.
[9] KIM J,BAE JS.Tumor-associated macrophages and neutrophils in tumor microenvironment [J].Mediators Inflamm,2016,2016:6058147.
[10] COFFELT SB,WELLENSTEIN MD,DE VISSER KE.Neutrophils in cancer:neutral no more [J].Nat Rev Cancer,2016,16(7):431-446.
[11] WANG M,CHANG M,LI C,et al.Tumor-microenvironment-activated reactive oxygen species amplifier for enzymatic cascade cancer starvation/chemodynamic /immunotherapy [J].Adv Mater,2022,34(4):e2106010.
[12] LAZENNEC G,RAJARATHNAM K,RICHMOND A.CXCR2 chemokine receptor-a master regulator in cancer and physiology [J].Trends Mol Med,2024,30(1):37-55.
[13] GAY LJ,FELDING-HABERMANN B.Contribution of platelets to tumour metastasis [J].Nat Rev Cancer,2011,11(2):123-134.
[14] CEDERVALL J,HAMIDI A,OLSSON AK.Platelets,NETs and cancer [J].Thromb Res,2018,164 Suppl 1:S148-s152.
[15] WANG L,WANG X,GUO E,et al.Emerging roles of platelets in cancer biology and their potential as therapeutic targets [J].Front Oncol,2022,12:939089.
[16] UPTON JEM,E GRUNEBAUM,G SUSSMAN,et al.Platelet activating factor (PAF):A mediator of inflammation [J].Biofactors,2022,48(6):1189-1202.
[17] LI Y,ZHAO L,LI XF.Hypoxia and the tumor microenvironment [J].Technol Cancer Res Treat,2021,20:15330338211036304.
[18] YANG L,PANG Y,MOSES HL.TGF-beta and immune cells:an important regulatory axis in the tumor microenvironment and progression [J].Trends Immunol,2010,31(6):220-227.
[19] 张宇,汪亦民,薛英威.全身免疫炎症指数(SII)与胃癌患者临床病理因素及预后的相关性[J].现代肿瘤医学,2021,29(3):441-445.
ZHANG Y,WANG YM,XUE YW.Relationship between systemic immune-inflammatory index(SII) and clinical pathological features and prognosis in patients with gastric cancer[J].Modern Oncology,2021,29(3):441-445.
[20] 张立志,刘平,吉慧军,等.全身免疫炎症指数(SII)对胶质瘤患者临床预后的影响及与p53突变的关系[J].现代肿瘤医学,2018,26(24):3937-3943.ZHANG LZ,LIU P,JI HJ,et al.Systemic immune-inflammation index(SII) in patients with glioma and its relationship with p53 mutation[J].Modern Oncology,2018,26(24):3937-3943.
[21] CHEN JH,ZHAI ET,YUAN YJ,et al.Systemic immune-inflammation index for predicting prognosis of colorectal cancer [J].World J Gastroenterol,2017,23(34):6261-6272.
[22] LI W,MA G,DENG Y,et al.Systemic immune-inflammation index is a prognostic factor for breast cancer patients after curative resection [J].Front Oncol,2021,11:570208.
[23] ANPALAKHAN S,SIGNORI A,CORTELLINI A,et al.Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors:An INVIDIa-2 study sub-analysis [J].iScience,2023,26(11):107970.
[24] HU B,YANG XR,XU Y,et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma [J].Clin Cancer Res,2014,20(23):6212-6222.
[25] SUN W,ZHANG P,YE B,et al.Systemic immune-inflammation index predicts survival in patients with resected lung invasive mucinous adenocarcinoma [J].Transl Oncol,2024,40:101865.
[26] BISWAS T,KANG KH,GAWDI R,et al.Using the systemic immune-inflammation index (SII) as a mid-treatment marker for survival among patients with stage-III locally advanced non-small cell lung cancer (NSCLC) [J].Int J Environ Res Public Health,2020,17(21).
[27] CRISTINZIANO L,MODESTINO L,ANTONELLI A,et al.Neutrophil extracellular traps in cancer [J].Semin Cancer Biol,2022,79:91-104.
[28] MIYAMOTO R,INAGAWA S,SANO N,et al.The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients [J].Eur J Surg Oncol,2018,44(5):607-612.
[29] RUBENICH DS,DE SOUZA PO,OMIZZOLLO N,et al.Tumor-neutrophil crosstalk promotes in vitro and in vivo glioblastoma progression [J].Front Immunol,2023,14:1183465.
[30] 唐文超,李远伟,陈佳,等.术前预后营养指数及中性粒-淋巴细胞比值在非肌层浸润性膀胱癌患者复发中的预测价值[J].现代肿瘤医学,2022,30(12):2218-2223.
TANG WC,LI YW,CHEN J,et al.The predictive value of preoperative PNI and NLR for recurrence of non-muscular invasive bladder cancer[J].Modern Oncology,2022,30(12):2218-2223.